Screener
Rhythm Pharmaceuticals, Inc. RYTM Debt Repayments
Debt Repayments at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RepaymentsOfLongTermDebt.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Maturities of short-term investments | 99,251 | 58,333 |
| Net cash provided by investing activities | 57,052 | 24,812 |
| Financing activities | ||
| Repayment of deferred royalty obligation | (4,288) | (4,615) |
| Proceeds from the exercise of stock options | 6,095 | 2,226 |
| Tax withholding on vesting of restricted stock | (8,458) | — |
| Proceeds from issuance of common stock from ESPP | 1,251 | 854 |
| Proceeds from ATM equity offering | — | 34,034 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s debt repayments?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported debt repayments of $4.29M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s debt repayments changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s debt repayments decreased by 7.1% year-over-year, from $4.62M to $4.29M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s debt repayments?
- Over 2 years (2023 to 2025), Rhythm Pharmaceuticals, Inc.'s debt repayments has grown at a 64.1% compound annual growth rate (CAGR), from $7.4M to $19.92M.
- What does debt repayments mean?
- Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s debt repayments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude